Empowering Health

ODI Pharma is a pharmaceutical company specialized in medicinal cannabis.

Since 2018 - with the goal to improve patients' lives.

Based on its European network, subsidiaries and partners, ODI is a producer and representative of pharmaceutical cannabis finished products under governmental supervision and regulation with a focus on distribution to medicinal markets, initially targeting Eastern Europe. Currently, ODI has distribution contracts representing supply contracts to 14,000+ pharmacies, hundreds of specialty clinics and multiple hospitals. We strive to provide consistent high quality, medical grade pharmaceuticals that fulfill strictest market standards. Our team is dedicated and committed to support the medical industry to implement the evolution of medicinal cannabis.

News & Press Release

News

Publication of interim report Q1 2025/2026

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - September 2025. The report is available as an attached document to this press release and on the Company's website ( www.odipharma.com ). Below is a summary of the report. First quarter (2025-07-01 – 2025-09-30) · The Group's net sales amounted to SEK 5,968,143 (143,793). · The Group's profit after financial items amounted to SEK -37,027 (-1,468,183). ·

vor 6 Tagen2 Min. Lesezeit

ODI Pharma demonstrates clear operational progress and improved commercial outlook

ODI Pharma AB (“ODI Pharma” or the “Company”) provides an operational update following recent improvements in its commercial performance. Strategic and practical measures implemented in recent quarters have begun to show clear results, supported by a more stable regulatory environment and smoother product flows into the Polish market. ODI Pharma’s commercial activity has strengthened in recent months as earlier operational and strategic measures begin to take effect. The Co

24. Nov.2 Min. Lesezeit

ODI Pharma AB publishes the annual report for the fiscal year 2024/2025

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2024/2025. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma ( www.odipharma.com ) and Spotlight Stock Market ( www.spotlightstockmarket.com ). The auditor has made the following observation: Material uncertainty relating to going concern Without quali

21. Nov.2 Min. Lesezeit

Our Mission

It is ODI's mission to promote and make the product available to patients in need in a controlled environment to prevent any negative side effects. The cannabis plant was neglected in the pharmaceutical industry for a period too long. We support additional research to improve the safeness of usage of the product even further.

14k+

Pharmacies

Instant access to pharmacies purchasing the products

100+

Clinics

We reach most clinics, researching and prescribing medicinal cannabis in Europe

23

countries in Europe

With our distribution network we reach up to almost all countries in Europe

ODI Pharma AB - prime choice for your investment

Our Values

WHAT WE STAND FOR

Attentiveness

Expertise

Support

At ODI Pharma, we believe that there can be no value creation without the founding values that guide our action and form the basis of our corporate culture.

The ability to invest in people to improve relationship and moral standards as well as purely technical standards has proved highly positive. It is simple values, such as kindness, compassion, empathy, availability, trust and educational support, that give ODI Pharma the reputation, just as much as performance in terms of skills and expertise.

We strive to make all our products available to those who are in need in order to live a full and enjoyable life.

Our success is based on expertise. Expertise is the cornerstone of ODI Pharma. It is applied in the selection of our business partners, research partners and all our financial decisions. There are no short-cuts in a developing an industry. Thorough due diligence and project evaluation is key to succeed in our industry.

Expertise drives us to maintain and improve our status through training, research and continuing education. We share our expertise with our clients so our clients don’t have to invest in building infrastructure.

ODI Pharma is viewed as the team who leads the evolution of a regulated medicinal cannabis market in Europe.

ODI Pharma puts high emphasis on the support of the dynamic medical cannabis market, its market participants, but first and foremost our clients, patients and medical practitioners.

We are continuously supporting research projects to better understand the product and the development of new applications.

Communication is an essential quality that ODI Pharma strives to apply to its day-to-day operations.

Medicinal Cannabis

Today, medicinal cannabis is a catch-all term for anything from dried cannabis flowers, cannabis oils, capsules, tablets, oromucosal spray and so on. But common to all of these product types is that...